Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinic Acetylcholine Receptor Alpha3Beta4 Subtype (α3β4 nAChR)
- Target
- α3β4 nAChR
- Molecular classification
- Ligand-gated ion channel, Receptor
01
Overview
The nicotinic acetylcholine receptor (nAChR) alpha3beta4 subtype is a pentameric ligand-gated ion channel composed of α3 and β4 subunits. It is predominantly expressed in autonomic ganglia and the adrenal medulla, mediating fast synaptic transmission. Polymorphisms in the genes encoding these subunits are associated with increased risk for nicotine dependence and other diseases. The receptor plays key roles in autonomic regulation and modulation of reward pathways, making it a potential therapeutic target for smoking cessation and other substance use disorders.
- Other names
- Ganglion-type nicotinic receptor
02
Mechanism of action
Agonist or antagonist binding to the receptor, leading to changes in ion channel conductance and neuronal excitability.
03
Biological functions
Fast synaptic transmissionAutonomic regulationReward pathway modulationIon transport
04
Disease associations
Nicotine dependenceLung cancerChronic obstructive pulmonary diseaseAlcoholismPeripheral arterial diseaseSubstance use disorders
05
Safety considerations
Non-selective agonists may have broad effects due to targeting multiple nAChR subtypes.Ganglionic blockade can have significant cardiovascular and other autonomic side effects.
06
Interacting drugs
Acetylcholine
8 more in the full profile.
Beyond the preview
Go deeper on Nicotinic Acetylcholine Receptor Alpha3Beta4 Subtype (α3β4 nAChR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor Alpha3Beta4 Subtype (α3β4 nAChR).